David L. Rose
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
David L. Rose has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Nicholas Karnezis
Department of Pathology and Laboratory Medicine, University of California, Davis, CA 95817, USA
3 shared publications - Apurva M. Hegde
Cancer & Cell Biology Division, Translational Genomics Research Institute, Phoenix, Arizona
3 shared publications - Bernard E. Weissman
The University of North Carolina at Chapel Hill
3 shared publications - David G. Huntsman
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
3 shared publications - Elizabeth A. Raupach
Integrated Cancer Genomics, Translational Genomics Research Institute, Phoenix, Arizona
3 shared publications - Jeffrey M. Trent
Translational Genomics Research Institute Phoenix Arizona USA
3 shared publications
Latest Publications
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Loss of SMARCA4 Leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic Type
Supplementary Tables from Loss of SMARCA4 Leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic Type
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Loss of SMARCA4 Leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic Type
Supplementary Tables from Loss of SMARCA4 Leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic Type
- Open Access
- 23 May 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (14) , 2626-2642
Loss of SMARCA4 Leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic Type
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is a rare, deadly form of ovarian cancer that uniformly harbors mutations in SMARCA4, a member of the SWI/SNF chromatin remodeling complex. SWI/SNF impacts RNA splicing, and dysregulation of splicing can generate immunogenic tumor antigens. In this study, we explored the relationship between SMARCA4 loss and RNA splicing dysregulation. SCCOHT primary tumors harbored tumor-associated outlier splicing events compared with normal tissues. Many of the tumor events were retained introns encoding novel peptides predicted to bind to MHC-I complexes. Immune cells were observed in primary SCCOHT tumors, suggesting a potentially immune-reactive tumor microenvironment. Mutations in several switch/sucrose nonfermenting (SWI/SNF) subunits were associated with higher rates of outlier retained introns across tumor types in The Cancer Genome Atlas data. Interestingly, RNA sequencing of isogenic SCCOHT cell lines demonstrated a role for SMARCA4 in intron retention (IR). Distinct protein–protein interactions between splicing factors identified in SCCOHT cell lines supported a role for SMARCA4 in splicing regulation. Furthermore, SWI/SNF localized to genes, which were differentially spliced. Mass spectrometry analyses confirmed expression of some of these novel peptides, and a subset of these are predicted to bind to MHC-I complexes. A pool of these novel peptides derived from retained introns in SCCOHT triggered proliferation and expression of TNFα and INFγ in primary human T cells. Together, these data suggest that SMARCA4 loss in SCCOHT leads to IR. Furthermore, T-cell activation by novel peptides encoded by these tumor-specific splicing events suggests IR could be a source of tumor-associated antigens in SCCOHT. Significance: SCCOHT, a rare ovarian cancer, features splicing dysregulation due to SMARCA4 loss that generates immunostimulatory peptides linked to potential immune responses and therapeutic avenues, challenging traditional views of the role of SMARCA4.
- 23 May 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (14) , 2626-2642
Open AccessLoss of SMARCA4 Leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic Type
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is a rare, deadly form of ovarian cancer that uniformly harbors mutations in SMARCA4, a member of the SWI/SNF chromatin remodeling complex. SWI/SNF impacts RNA splicing, and dysregulation of splicing can generate immunogenic tumor antigens. In this study, we explored the relationship between SMARCA4 loss and RNA splicing dysregulation. SCCOHT primary tumors harbored tumor-associated outlier splicing events compared with normal tissues. Many of the tumor events were retained introns encoding novel peptides predicted to bind to MHC-I complexes. Immune cells were observed in primary SCCOHT tumors, suggesting a potentially immune-reactive tumor microenvironment. Mutations in several switch/sucrose nonfermenting (SWI/SNF) subunits were associated with higher rates of outlier retained introns across tumor types in The Cancer Genome Atlas data. Interestingly, RNA sequencing of isogenic SCCOHT cell lines demonstrated a role for SMARCA4 in intron retention (IR). Distinct protein–protein interactions between splicing factors identified in SCCOHT cell lines supported a role for SMARCA4 in splicing regulation. Furthermore, SWI/SNF localized to genes, which were differentially spliced. Mass spectrometry analyses confirmed expression of some of these novel peptides, and a subset of these are predicted to bind to MHC-I complexes. A pool of these novel peptides derived from retained introns in SCCOHT triggered proliferation and expression of TNFα and INFγ in primary human T cells. Together, these data suggest that SMARCA4 loss in SCCOHT leads to IR. Furthermore, T-cell activation by novel peptides encoded by these tumor-specific splicing events suggests IR could be a source of tumor-associated antigens in SCCOHT. Significance: SCCOHT, a rare ovarian cancer, features splicing dysregulation due to SMARCA4 loss that generates immunostimulatory peptides linked to potential immune responses and therapeutic avenues, challenging traditional views of the role of SMARCA4.
- Open Access
- 1 July 1997
- Published by Microbiology Society in International Journal of Systematic and Evolutionary Microbiology
- Vol. 47 (3) , 759-762
Spiroplasma alleghenense sp. nov., a New Species from the Scorpion Fly Panorpa helena (Mecoptera: Panorpidae)
Spiroplasma strain PLHS-lT from the gut of a common scorpion fly (Panorpa helena) collected in the West Virginia Allegheny Mountains was distinct from other spiroplasma species, groups, and subgroups as deter- mined by reciprocal serological metabolism inhibition and deformation tests. However, when this strain was used as an antigen, it cross-reacted extensively with representatives of other groups. Light microscopy and/or electron microscopy of cells of strain PLHS-lT revealed helical motile cells surrounded by a single cytoplasmic membrane. The strain was resistant to penicillin, which confirmed that it had no cell wall. The organism grew well in M1D and SP-4 liquid media, in 1% serum fraction medium, and in conventional horse serum medium. The optimum temperature for growth was 30°C, at which the doubling time was 6.4 h. Multiplication occurred at temperatures from 10 to 32°C. Strain PLHS-lT catabolized glucose, hydrolyzed arginine but not urea, and required sterol for growth. The guanine-plus-cytosine content of the DNA was 31 f 1 mol%, and the genome size was 1,465 kbp. Strain PLHS-1 (= ATCC 51752) is designated the type strain of a new species, Spiroplasma alleghenense.
- 1 July 1997
- Published by Microbiology Society in International Journal of Systematic and Evolutionary Microbiology
- Vol. 47 (3) , 759-762
Open AccessSpiroplasma alleghenense sp. nov., a New Species from the Scorpion Fly Panorpa helena (Mecoptera: Panorpidae)
Spiroplasma strain PLHS-lT from the gut of a common scorpion fly (Panorpa helena) collected in the West Virginia Allegheny Mountains was distinct from other spiroplasma species, groups, and subgroups as deter- mined by reciprocal serological metabolism inhibition and deformation tests. However, when this strain was used as an antigen, it cross-reacted extensively with representatives of other groups. Light microscopy and/or electron microscopy of cells of strain PLHS-lT revealed helical motile cells surrounded by a single cytoplasmic membrane. The strain was resistant to penicillin, which confirmed that it had no cell wall. The organism grew well in M1D and SP-4 liquid media, in 1% serum fraction medium, and in conventional horse serum medium. The optimum temperature for growth was 30°C, at which the doubling time was 6.4 h. Multiplication occurred at temperatures from 10 to 32°C. Strain PLHS-lT catabolized glucose, hydrolyzed arginine but not urea, and required sterol for growth. The guanine-plus-cytosine content of the DNA was 31 f 1 mol%, and the genome size was 1,465 kbp. Strain PLHS-1 (= ATCC 51752) is designated the type strain of a new species, Spiroplasma alleghenense.
- Open Access
- 1 July 1997
- Published by Microbiology Society in International Journal of Systematic and Evolutionary Microbiology
- Vol. 47 (3) , 720-723
Spiroplasma montanense sp. nov., from Hybomitra Horseflies at Northern Latitudes in North America
- 1 July 1997
- Published by Microbiology Society in International Journal of Systematic and Evolutionary Microbiology
- Vol. 47 (3) , 720-723
Open AccessSpiroplasma montanense sp. nov., from Hybomitra Horseflies at Northern Latitudes in North America